Dimensional Fund Advisors LP Increases Stock Holdings in Masimo Corporation $MASI

Key Points

• Dimensional Fund Advisors LP has increased its ownership in Masimo Corporation by 8.6%, owning approximately 703,378 shares valued at $117.17 million.
• In the first quarter, several institutional investors increased their stakes in Masimo, with ownership by institutional investors totaling 85.96% of the company's stock.
• Masimo's latest earnings report exceeded expectations, with an EPS of $1.33 and revenues of $370.9 million, marking a 7.7% year-over-year increase.

Dimensional Fund Advisors LP lifted its holdings in Masimo Corporation (NASDAQ:MASI - Free Report) by 8.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 703,378 shares of the medical equipment provider's stock after acquiring an additional 55,658 shares during the quarter. Dimensional Fund Advisors LP owned 1.30% of Masimo worth $117,172,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC increased its stake in shares of Masimo by 58.4% in the first quarter. GAMMA Investing LLC now owns 738 shares of the medical equipment provider's stock worth $123,000 after acquiring an additional 272 shares during the period. NBC Securities Inc. acquired a new stake in shares of Masimo in the first quarter worth $61,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Masimo by 2.9% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,039 shares of the medical equipment provider's stock worth $673,000 after acquiring an additional 115 shares during the period. UMB Bank n.a. boosted its holdings in Masimo by 134.0% during the first quarter. UMB Bank n.a. now owns 447 shares of the medical equipment provider's stock worth $74,000 after buying an additional 256 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Masimo by 259.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 250,786 shares of the medical equipment provider's stock worth $41,456,000 after buying an additional 181,070 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Price Performance

Shares of NASDAQ MASI traded down $3.48 during mid-day trading on Monday, reaching $145.15. The company's stock had a trading volume of 467,394 shares, compared to its average volume of 891,980. The stock has a 50-day moving average of $158.85 and a two-hundred day moving average of $162.54. The stock has a market capitalization of $7.89 billion, a P/E ratio of -17.04 and a beta of 1.21. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. Masimo Corporation has a 1-year low of $107.98 and a 1-year high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 EPS for the quarter, beating analysts' consensus estimates of $1.22 by $0.11. The business had revenue of $370.90 million during the quarter, compared to analysts' expectations of $368.65 million. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The company's quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.86 earnings per share. On average, equities research analysts anticipate that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director William R. Jellison acquired 3,000 shares of the stock in a transaction on Monday, August 11th. The shares were bought at an average price of $145.98 per share, with a total value of $437,940.00. Following the completion of the purchase, the director owned 4,790 shares of the company's stock, valued at approximately $699,244.20. This represents a 167.60% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 16.90% of the company's stock.

Analyst Upgrades and Downgrades

MASI has been the topic of a number of recent analyst reports. BTIG Research reissued a "buy" rating on shares of Masimo in a report on Thursday, August 14th. Wells Fargo & Company lowered their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Raymond James Financial dropped their price objective on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Piper Sandler raised their price objective on Masimo from $200.00 to $210.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Finally, Wall Street Zen lowered Masimo from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $193.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.